CVT-ISR First in Human Trial for Coronary In-Stent Restenosis

NCT05731700 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-05-15

Study results available
· View outcomes & findings →

Summary

The goal of this first in human study is to assess the safety and inhibition of restenosis of the CVT Everolimus-coated PTCA Catheter in the treatment of subjects presenting in-stent restenotic lesions in native coronary arteries.

Conditions

  • In-stent Restenosis

Interventions

DEVICE

Drug Eluting Balloon

PCI of in-stent restenosis

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-20
Primary Completion
2022-09-19
Completion
2025-05-08

Countries

  • France
  • Georgia
  • Lithuania
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05731700 on ClinicalTrials.gov